Saturday 17 October 2026
Export BBNX’s income statement to Excel — free account
Beta Bionics, Inc.
BBNX Healthcare Medical Devices
Beta Bionics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.3 million, up 53.9% from fiscal 2024. In the quarter to June 2026, revenue grew 37.8%, EPS fell 35.9% and free cash flow fell 1.87%, each against the same quarter a year earlier.
16.35
0.96
−5.55%
Follow BBNX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 8.89 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 32.71 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 294 | 294 | 423 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.04 | 0.22 | 0.24 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 12 | 65 | 100 | ||||
| Gross margin, % | — | — | — | — | — | — | — | 52.59 | 55.11 | 55.40 | |||||
| EBT | — | — | — | — | — | — | — | (44) | (55) | (73) | |||||
| EBT margin, % | — | — | — | — | — | — | — | (367.64) | (84.08) | (73.02) | |||||
| Net income | — | — | — | — | — | — | — | (44) | (55) | (73) | |||||
| Depreciation | — | — | — | — | — | — | — | 2 | 2 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 2.26 | 10.23 | 2.47 | ||||
| Earnings | — | — | — | — | — | — | — | (8.31) | (8.60) | (1.81) | |||||
| Cash flow | — | — | — | — | — | — | — | (6.12) | (7.58) | (1.26) | |||||
| Capex | — | — | — | — | — | — | — | (0.07) | (11.32) | (6.96) | |||||
| Free cash flow | — | — | — | — | — | — | — | (6.19) | (18.91) | (8.22) | |||||
| Book value | — | — | — | — | — | — | — | (38.29) | (38.55) | 7.10 | |||||
| Shares, m | — | — | — | — | — | — | — | 5 | 6 | 41 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | 2.42 | 2.42 | 12.32 | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 4.29 | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.83 | 0.83 | 10.13 | |||||
| EV/FCF | — | — | — | — | — | — | — | (1.04) | (1.04) | (3.05) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (32) | (48) | (51) | ||||
| Capex | — | — | — | — | — | — | — | 0 | (72) | (282) | |||||
| Free cash flow | — | — | — | — | — | — | — | (33) | (120) | (333) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 93 | 112 | 237 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | (97) | (104) | (219) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (203) | (245) | 288 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (42.17) | (30.60) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | 0.00 | (65.51) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | 24.42 | (346.51) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Beta Bionics, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CBLL CeriBell, Inc. | $1.1B | — (loss-making) | — (loss-making) | +32.54% (above 0%: growing) | n/m | −68.63% (below 0%: shrinking) | 92.32% | (71.11%) | Compare |
| IART Integra LifeSciences Holdings Corporation | $1.1B | — (loss-making) | 26.1× | +0.76% (above 0%: growing) | n/m | +193.48% (above 0%: growing) | 52.47% | 4.61% | Compare |
| LMRI Lumexa Imaging Holdings, Inc. | $1.0B | — (loss-making) | 14.2× | +7.82% (above 0%: growing) | n/m | +257.54% (above 0%: growing) | 14.72% | 8.72% | Compare |
| PRCT PROCEPT BioRobotics Corporation | $1.0B | — (loss-making) | — (loss-making) | +19.34% (above 0%: growing) | n/m | −24.43% (below 0%: shrinking) | 66.01% | (28.98%) | Compare |
| QDEL QuidelOrtho Corporation | $953.9M | — (loss-making) | — (loss-making) | +2.77% (above 0%: growing) | n/m | −61.45% (below 0%: shrinking) | 43.26% | (3.46%) | Compare |
| BBNX Beta Bionics, Inc. | $933.8M | — (loss-making) | — (loss-making) | +37.76% (above 0%: growing) | n/m | −1.87% (below 0%: shrinking) | 59.04% | (79.90%) | |
| SIBN SiBone | $892.3M | — (loss-making) | — (loss-making) | +15.18% (above 0%: growing) | n/m | +60.12% (above 0%: growing) | 79.54% | (8.58%) | Compare |
| AHCO AdaptHealth Corp. | $871.2M | — (loss-making) | 13.2× | +12.66% (above 0%: growing) | n/m | −128.56% (below 0%: shrinking) | 14.08% | (18.61%) | Compare |
| INMD InMode Ltd. | $824.0M | 11.3× | 11.8× | −0.01% (below 0%: shrinking) | −30.95% (below 0%: shrinking) | −12.63% (below 0%: shrinking) | 74.82% | 12.82% | Compare |
| Median of peers | $996.9M | — | 13.7× | +10.24% | — | −18.53% | 59.24% | (6.02%) |
Beta Bionics, Inc. (BBNX) key facts
- Strength: Beta Bionics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.3 million, up 53.9% from fiscal 2024.
- Beta Bionics, Inc. (BBNX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, BBNX traded at $16.35, a market capitalization of $933.8 million.
- Return on equity was −346.5% and debt-to-equity 0.00.
- Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 16.89 (safe zone) for fiscal 2025.